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Hundreds of post-translational modifications (PTM) have been
characterized on proteins, including a large variety of glycosyla-
tions, among which figures O-GlcNAcylation. Since its discovery,
O-GlcNAcylation has emerged as a major PTM that is wide-
spread, being found in viruses, bacteria, and protists through
plant and animal cells. In contrast to N - and O-glycosylations,
O-GlcNAcylation involves only the transfer of a single N -
acetylglucosamine moiety through a beta-linkage onto serine and
threonine residues of proteins that are localized to the cytosol,
nucleus, and mitochondria. The O-GlcNAc group is provided by
UDP–GlcNAc, the end-product of the hexosamine biosynthetic
pathway (HBP), which integrates several metabolic pathways. O-
GlcNAcylation levels therefore tightly depend on the nutritional
status; regulation of functions by this PTM is thus intimately linked
to lifestyle and environment (1, 2). As with phosphorylation,
with which it can compete,O-GlcNAcylation is reversible through
opposing actions of O-GlcNAc transferase (OGT) that transfers
the GlcNAc group, andO-GlcNAcase (OGA) that removes it. Also,
like its unsweetened counterpart, O-GlcNAcylation controls fun-
damental processes, e.g., protein fate, chromatin topology, DNA
demethylation, and the circadian clock. Deregulation of the mech-
anisms controlling O-GlcNAc dynamics may be involved in the
development of cancers, neuronal disorders such as Alzheimer’s
disease, and metabolic conditions such as diabetes (1, 2).
This E-Book, which gathers Original Research papers, Method
Articles, and Reviews published as part of a Research Topic in Fron-
tiers in Endocrinology, is the opportunity to celebrate the thirtieth
anniversary of the discovery of “O-GlcNAc.”
Honor to whom honor is due, it is to Gerald W. Hart, the dis-
coverer of O-GlcNAc (3), that was assigned the task of writing a
historical “Perspective” (4) as an introduction to this “Research
Topic.”
Protein O-GlcNAcylation levels in cells, resulting from the
opposing actions of OGT and OGA, are tightly regulated. Most
people working in the field have experienced the now common-
place observation that manipulating cellular O-GlcNAc levels
using drugs, siRNA or cDNA transfection results in counter-
regulatory modification in OGT and OGA expression. However,
no study had been specifically dedicated to investigate this ques-
tion. In an original paper by Zhang et al. (5) the effect of a potent
and highly selective OGA inhibitor, Thiamet-G, on OGT and OGA
mRNA and protein levels, was systematically studied in different
cell types. The authors observed that OGA is more sensitive than
OGT to O-GlcNAc levels. Increases in OGA expression were not
due to stabilization of OGA mRNA or protein, suggesting regu-
lation of OGA mRNA via transcription, through as yet unknown
mechanisms.
O-GlcNAcylation is generally presented as a glycosylation
that occurs only in the cytosol, the nucleus, and to a lesser
extent, in mitochondria, in contrast to “classical” and complex N -
and O-glycosylations that take place in the endoplasmic reticu-
lum and the Golgi apparatus, and that modify transmembrane,
secreted and organelle-confined proteins. However, biology is
often made of exceptions to rules, and O-GlcNAcylation of pro-
tein extracellular domains has been demonstrated in Drosophila
(6). In this Research Topic, Nagnan-Le Meillour et al. (7) provide
original data indicating that olfactory binding proteins (OBPs)
secreted in pig nasal mucus are also modified by O-GlcNAc. They
identified and cloned a conserved eOGT (EGF domain-specific
OGT) in Sus scrofa and proposed that O-GlcNAcylation of OBPs
could finely modulate their binding specificities for odors and
pheromones.
Increased O-GlcNAcylation is involved in insulin resistance
associated with diabetes and obesity (2). The adipose cell plays a
central role in the regulation of energy homeostasis, in particular,
through its capacity to secrete adipokines that modulate insulin
sensitivity and pro-inflammatory cytokines. Wollaston-Hayden
et al. (8) show that O-GlcNAc modulates the transcript levels of
multiple secreted proteins in rodent adipocytes, and propose that
O-GlcNAcylation of transcription factors such as Sp1 plays a role
in adipokines gene transcription during insulin resistance.
Whereas OGT or OGA knock down is lethal in higher eukary-
otes, ogt1 and oga1 null C. elegans are viable. Taking advantage
of this model organism, Ghosh et al. (9) investigated the conse-
quences of OGT or OGA ablation, and showed that disruption
in O-GlcNAc cycling alters nucleotide sugar production, over-
all glycan composition and transcription of genes encoding key
members of the HBP pathway.
Although more than 1000 proteins are already known targets
for O-GlcNAcylation, it is likely that numerous O-GlcNAcylated
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proteins remain to be identified. In addition, one of the fas-
cinating features of O-GlcNAc is its complex interplay with
phosphorylation (1), either through regulation of phospho-
rylation at adjacent sites or by direct competition between
O-GlcNAcylation and phosphorylation for the same site (the
so-called Yin–Yang mechanism). In a Methods article, Cieniewski-
Bernard et al. (10) describe the development of a multiplex,
fluorescence-based proteomic strategy that permits to detect
O-GlcNAcylated proteins, phosphoproteins, and the whole pro-
teome on the same bi-dimensional gel.
This Research Topic also includes a number of reviews on some
of the important biological and pathophysiological questions
linked to O-GlcNAcylation. The perturbation of the O-GlcNAc
cycle recently appeared as a hallmark of cancer cells (11). Józ´wiak
et al. (12) review the role of O-GlcNAc in metabolic reprograming
of cancer cells, through modification of metabolic enzymes, sig-
naling proteins, and transcription factors, and Chaiyawat et al. (13)
discuss these alterations specifically in breast and colorectal can-
cers. Epigenetic alterations also characterize numerous tumors,
and recent data reviewed by Dehennaut et al. (14) reveal the
involvement of O-GlcNAcylation as an epigenetic mark, and its
role in chromatin remodeling and DNA methylation.
Numerous studies have provided evidence that O-GlcNAc neg-
atively regulates insulin signaling (2), highlighting a link between
hyperglycemia, insulin resistance, and glucotoxicity. Zhang et al.
(15) review the implication of O-GlcNAcylation of signaling com-
ponents and transcription factors in normal liver metabolism and
in liver diseases, including insulin resistance, non-alcoholic fatty
liver disease, and non-alcoholic steatohepatitis.
In a mini review, Benahmed et al. (16) also discuss the role
of transcription factors in the control of energy metabolism, and
more specifically the antagonistic relationships between ChREBP,
which controls the expression of glycolytic and lipogenic genes,
and the nuclear receptor FXR, which controls bile acid metabolism
involved in gut–liver homeostasis. Interestingly, both transcription
factors are modified by O-GlcNAcylation, although the conse-
quences of this modification on ChREBP–FXR interaction remain
to be explored.
Finally, as several lines of evidence indicate that O-
GlcNAcylation regulates immune processes and may participate
in hyperglycemia-associated inflammation, Baudoin and Issad
(17) review the pro- and anti-inflammatory effects of O-GlcNAc,
which may appear contradictory depending on cell types and
pathophysiological situations. The field reviewed by these authors
illustrates the complexity of signaling pathway regulation by
O-GlcNAcylation. The control of inflammatory processes by
O-GlcNAcylation is one of the innumerable Terra incognita to
be explored.
Although not all aspects of O-GlcNAc biology could be pre-
sented in the Research Topic, we hope that it will excite the
curiosity and stimulate the interest of young scientists for this
ever-expanding, fascinating field.
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